ImClone Systems to Host Investor Reception on June 5, 2007 Following a Clinical Science Symposium Session about EGFR as a Therapeutic Target in GI Malignancy
Friday June 1, 1:10 pm ET
NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL - News) announced today that the Company will host an investor reception on Tuesday, June 5, 2007 from 3:45 P.M. to 5:00 P.M. Central Time in the Conference Center, Room 11A at the Hyatt Regency McCormick Place Hotel (2233 South Martin Luther King Drive, Chicago, IL) following the conclusion of the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The investor reception follows an ASCO clinical science symposium session on June 5, 2007 entitled, "The Epidermal Growth Factor Receptor as a Therapeutic Target in Gastrointestinal Malignancy." ImClone's targeted cancer therapy ERBITUX® (cetuximab) will be highlighted in four (4) presentations to be delivered during the symposium. The ERBITUX presentations during the symposium will be:
Randomized phase III study of irinotecan and 5 FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial from 11:00 AM to 11:15 AM.
EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer, 11:15 AM to 11:30 AM.
Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial, 11:45 AM to 12:00 PM.
Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial, 12:00 PM to 12:15 PM.
Members of the ImClone Systems' management team will be available during the reception to discuss questions regarding the data that was presented on ERBITUX (cetuximab) and the Company's pipeline during the ASCO meeting.
